News & Events about Stockal+Disclaimer.pdf.
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON...
AEON Biopharma, Inc. (AEON or the Company), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., (Nasdaq: PMGM) (Priveterra), a special purpose acquisition company, today...
Topline data expected to be announced in 2H 2023 Topline data from the Companys Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (AEON or the Company), a private clinical-stage ...
ALISO VIEJO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the appointment of three new members to its Board of Directors effective as of the closing of the Companys initial public offering on August 3, 2021. The three appointments, ...